辉瑞mRNA流感疫苗三期数据显示其效力比标准疫苗高出34.5%

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to a control vaccine.